Qanatpharma AG

Qanatpharma (QP) is a Phase 2 clinical-stage biopharma company developing innovative therapies for diseases where microvascular dysfunction is a central feature. QP manages a pipeline that spans from microvascular target discovery and validation via AI-driven drug development to preclinical studies and, ultimately, clinical trials.